Daniel Otzen, PhD, Aarhus University, Aarhus, Denmark, comments on the role of glycation in Parkinson’s disease (PD) and explains how this process could be targeted to treat this disease. Prof. Otzen explains that whilst α-synuclein glycation can reduce fibril formation, it can also lead to the formation of smaller cytotoxic oligomers. However, by finding the optimal number of post-translational modifications (PTMs), it is possible to effectively inhibit fibril elongation, thus opening a new therapeutic avenue for protein aggregation disorders. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.